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Abstract: Growing scientific evidence has unveiled increased incidences of obesity in domestic
animals and its influence on a plethora of associated disorders. Leptin, an adipokine regulating body
fat mass, represents a key molecule in obesity, able to modulate immune responses and foster chronic
inflammatory response in peripheral tissues. High levels of cytokines and inflammatory markers
suggest an association between inflammatory state and obesity in dogs, highlighting the parallelism
with humans. Canine obesity is a relevant disease always accompanied with several health conditions
such as inflammation, immune-dysregulation, insulin resistance, pancreatitis, orthopaedic disorders,
cardiovascular disease, and neoplasia. However, leptin involvement in many disease processes in
veterinary medicine is poorly understood. Moreover, hyperleptinemia as well as leptin resistance
occur with cardiac dysfunction as a consequence of altered cardiac mitochondrial metabolism in
obese dogs. Similarly, leptin dysregulation seems to be involved in the pancreatitis pathophysiology.
This review aims to examine literature concerning leptin and immunological status in obese dogs,
in particular for the aspects related to obesity-associated diseases.
Keywords: leptin; dog; obesity; immune function; physiology; human
1. Introduction
Obesity is a metabolic disorder arising due to abnormal and frequently ectopic white adipose tissue
deposition, as a consequence of an altered balance between energy intake and consumption, usually
dependent on the body’s inefficiency to convert caloric intake in energy. Literature has been focused
on the role of leptin in determining obesity and related diseases in humans. The economic impact of
obesity on the world health care system stimulated research interest [1] on the underlying molecular
and biochemical mechanisms of obesity-associated comorbidities such as diabetes mellitus, metabolic
disorders [2], orthopaedic disease [3], respiratory dysfunction [4], and altered renal function [5].
Growing incidences of obesity highlighted its relevance in domestic animals and, in particular,
in dogs [6].
From its first characterization in 1994 to today, the relationship between leptin and its involvement
in supporting inflammatory processes becomes increasingly relevant also in the determinism of
autoimmunity [7,8].
In this regard, white adipose tissue has been considered not only a fat storage compartment
able to regulate energy homeostasis, but also a key provider of several biomolecules able to deeply
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modulate tissue physiology in individuals [9–12]. Leptin production is mainly based on adipocytes
secretion, the level of such a hormone correlates with white adipose tissue mass and contributes to an
inflammatory state in overweight and obese humans [12]. In addition to the control of the biological
processes involved in energy homeostasis, leptin has systemic effects that include the regulation
of endocrine function, the immune response, and haematopoiesis [13–15]. Therefore, obesity can
be considered as a chronic and complex pathological state associated with multiple systemic and
tissue-specific alterations. This review intends to examine the physiological role of leptin, the possible
relationship between leptin, immune function, and metabolism in dogs, and to highlight possible
perspectives for human studies.
2. Physiological Role of Leptin and Its Relationship with Obesity
Leptin is a hormone secreted by white adipocytes [16,17]. Through the blood-brain barrier,
such a hormone reaches the hypothalamus to decrease food intake and to increase metabolism [16].
Leptin receptors, encoded by the LEPR gene [18,19], are expressed by hypothalamic satiety centres
and are widely disseminated throughout the body—this occurrence reflects the pleiotropic nature of
leptin that is involved in the control of many physiologic processes [20]. Ob-Rb, the ‘long’ isoform
of the receptor, is predominantly expressed in the hypothalamus [21–23], while the short isoforms
(Ob-Ra, Ob-Rc, Ob-Rd, and Ob-Rf) are expressed in the peripheral tissues [24,25]. Leptin receptor
(LEPR) needs the activation of receptor associated kinases of Janus family (JAKs), which in turn
induce downstream signalling involving different members of signal transducers and activators
of transcription (STAT) family [26]. Leptin receptors activate a complex neural circuit involving
anorexigenic (i.e., appetite-diminishing) and orexigenic (i.e., appetite-stimulating) neuropeptides to
control food intake.
Moreover, leptin also stimulates the sympathetic nervous system inducing an increase in plasma
norepinephrine and epinephrine concentrations via the ventromedial hypothalamus [27].
In addition to its pivotal role in the regulation of energy metabolism [28], leptin possesses
other important physiological activities as the control of neuroendocrine and immune functions,
and haematopoiesis [29,30]. The strict association between obesity and hematopoietic disruption evidenced
the role of leptin on bone organization. The direct role for leptin in haematopoiesis has been demonstrated by
the presence of Ob-R on bone marrow CD34+ cells as well as on lympho-haematopoietic and megakaryocytic
cell lines [31,32]. Recently, Claycombe et al. [33] demonstrated that myelopoiesis recover after treatment
with leptin in obese mice (ob/ob). Aberrant leptin levels in patients with haematological malignancies
have been described, suggesting that leptin signalling is involved in the progression of haematological
malignancies and could represent a useful prognostic value [34].
Relationship between leptin and obesity could be considered as a part of metabolic syndrome
(MS), the pathological condition comprising of also dyslipidaemia, hyperglycaemia, and high blood
pressure. It is noteworthy that obesity is related to the leptin receptor resistance mechanisms [35],
including several aspects such as: (i) Interruption of leptin signalling in hypothalamic and other
central nervous system (CNS) neurons; (ii) alteration of leptin transport across blood-brain barrier; (iii)
hypothalamic inflammation, autophagy, and endoplasmic reticulum stress [36,37]. The development
of leptin resistance and of hyperleptinemia have been widely demonstrated in humans and in domestic
animals [38].
In the course of obesity and hyperleptinemia condition, an accumulation of epicardial adipose
tissue has been demonstrated [39], suggesting its involvement in cardiovascular system damage.
Chronic inflammation and the accumulation of epicardial fat is strongly concomitant with coronary
artery disease, independent of visceral adiposity [39]. Furthermore, high circulating levels of leptin
appeared to induce significant impairment of the haemostatic balance in cardiovascular diseases [40].
Moreover, leptin has been associated to hypertension and congestive heart failure (HF) in humans,
dogs, and cats [38,41]. In addition, leptin accelerates atherosclerosis spreading [42].
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The role of leptin and adipokines on the cardiovascular system have been largely described to be
dependent on two mechanisms involving the heart or the central nervous system [43–45]. Leptin acts by
stimulating the migration and proliferation of vascular smooth muscle cells (VSMCs) [46]. Such hormones
block the vasoconstrictor action of angiotensin II and inhibits the angiotensin II-induced increase in
intracellular Ca2+ in VSMCs through Ob-Rb [47]. Leptin shows angiogenetic effects dependent on both
proliferation and migration of vascular smooth muscle cells by promoting the upregulation of vascular
endothelial growth factor (VEGF) expression [48] and the cytoskeleton reorganization [49].
Acute pancreatitis is associated with high levels of leptin in serum and pancreas [50,51], suggesting
the role for such a hormone as a marker for adipose tissue necrosis [52]. Intriguingly, the pancreas
could secrete leptin and its protective role in pancreatitis has been described [53,54]. In agreement
with this hypothesis, beneficial effects of leptin on acute pancreatitis have been evidenced in
ischemia/reperfusion [54,55].
3. Role of Leptin in the Relationship between Obesity and Immune-Modulation.
An interesting scenario on obesity is that immune response greedily needs “energy” to be
implemented. In a pathophysiological perspective, this energy can be in excess or in deficit. In this
regard, food opulence is frequently associated with autoimmune diseases [7,56,57], while hyponutrition
induces susceptibility to infectious diseases [58–61]. Therefore, an excess of nutrients could drive
the immune system towards self-reactivity, while a defect can determine insufficient anti-infectious
immune responses. In this regard, the relationship between obesity and immune modulation appears
of great relevance in both human and veterinary medicine [7,56,57,62–67].
In human and animal obesity, the secretion of leptin and other hormones from the adipose tissue
appears to determine the dysregulation of the immune response [7,68,69] (Figure 1).
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Figure 1. Inflammatory roles of leptin in the course of obesity and their relevance in both human and
veterinary medicine.
Moreover, leptin and its receptors are integral components of a complex physiological system
evolved to regulate fuel stores and energy balance at an optimum level in mammals [70].
Leptin has structural similarities with the alpha-helix family of cytokines and its receptor (ObR)
belongs to the superfamily of class I cytokine receptors [71]. Leptin receptors are expressed by immune
system cells [72–74], and leptin possesses modulatory effects on both innate and adaptive immunity [75,76]
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(Figure 2). Such a hormone is currently considered a pro-inflammatory adipokine [7,8,12]. In this regard,
leptin acts as an acute phase inflammatory cytokine like interleukin (IL)-1, IL-6, and tumour necrosis factor
(TNF)-α [29] and is necessary for phagocytosis of bacteria by polymorph nuclear cells [77].
Several studies evidenced the involvement of leptin in activation of macrophages [78] and in their
recruitment in adipose tissue [79] (Figure 2). Leptin fosters pro-inflammatory activity by monocyte [80]
and promotes their production of reactive oxygen species (ROS) [81,82] (Figure 2). Furthermore, such a
hormone plays an anti-apoptotic role in serum-deprived monocytes demonstrating that this adipokine
could act as a growth factor for these cells [83]. Leptin also exerts chemotactic activity on neutrophils [84]
and promotes their production of intracellular hydrogen peroxide [85] (Figure 2).
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Figure 2. Physiological role of leptin on innate and adaptive immunity.
Neutrophils express the short form of the leptin receptor [86] that can stimulate the expression of
CD11b and prevent apoptosis.
Dendritic cells (DC), a specialized cell population for antigen uptake in body tissues, express leptin
receptors (Ob-R) on their surface [87]. Leptin acts on these cells, favouring their differentiation, maturation,
recruitment, and survival [87,88] and modulating the signalling pathways involved in these biological
processes as observed in db/db mice lacking leptin receptors (Ob-R) [88]. Furthermore, an important role of
leptin is exercised by the activation and recruitment of the DC (Figure 2).
Deficits of leptin receptors in Natural Killer (NK) cells correlate with decreased NK number and
functions [89,90].
Moreover, LEPR-deficient (db/db) mice evidenced a decrease of NK function [91].
The role of leptin in adaptive immunity has been largely demonstrated from early studies on db/db
mice that showed high level of thymocyte apoptosis [92].
A great research interest has moved to explore the leptin role on the T and B cell population
(Figure 2). Leptin acts with several mechanisms on T lymphocytes and induces the expression of the
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long isoform of LEPR in CD4+ T cells [93]. Such adipokine promotes activation and proliferation of T
lymphocytes and enhances their cytokine production [94,95]. In addition, the leptin supplementation
to a mixed lymphocyte reaction has been observed to induce a proliferation of CD4+ T cells [95].
Leptin regulates the adaptive immunity, also influencing activities of T Helper (Th) 1 and
2 lymphocytes [7,8,58,96]. In particular, the hormone stimulates the Th1 production of cytokines such
as IL-2, interferon (IFN)-γ, TNF-α, and IL-18, and drives the differentiation of the Th17 cells mainly
involved in chronic inflammation establishment [97,98].
In addition, leptin influences B-cell activities, regulating and promoting cell cycle by Bcl-2 and
cyclin D activation [99].
It is of note that leptin acts on the homeostasis of a specific CD4+CD25highFoxp3+ T immune
regulatory cell population, usually referred to as Treg [7,100–104]. Such cells avoid the auto
reactivity of the immune system against the “self” molecular components that belong to the
individual itself [7,100–102]. Human Treg cells display heterogeneous gene expression, phenotype,
and suppressive functions [105]. This occurrence strongly correlates with the different splicing
variants of the transcriptional factor FoxP3 [106]—the full-length isoform (FoxP3fl), which contains the
sequences involved in the interaction with retinoic acid-related orphan receptors α and γt (RORα and
RORγt), is associated with Treg function in humans [107]. In contrast, the expression of the isoform
lacking exon 2 (FoxP3∆2) correlates with dysfunction of Treg cells, since it appears to be unable to
interact with RORα and RORγt [108]. FoxP3∆2 expression has been correlated with multiple sclerosis
in humans [109]. Expression of the different FOXP3 isoforms is conditioned by metabolic aspects [110]
and by the exposure of Treg to the pro-inflammatory micro-environment [111]. No data over this
potential functional dichotomy are available from canine or feline models.
Nutrient availability is essential for the maintenance of tissue homeostasis. In this context,
the intracellular “sensor” of nutrients [112] is represented by the mammalian target of rapamycin,
the mTOR molecule [113]. This serine–threonine kinase “senses” the extracellular bioavailability of
amino acids, glucose, growth factors, and hormones [101,112–114], promotes cell metabolism and
growth when the conditions are favourable; or catabolic processes when conditions are not favourable.
In this context, mTOR is strongly correlated with Treg homeostasis and functions [115]. High levels
of leptin correlate with a reduced number and with decreased functions of Treg cells in human
autoimmune diseases [7,56]. The relationship between metabolism and cell plasticity is of great
relevance, particularly for the homeostasis of immune system cells that are highly “sensitive” to
bioavailable nutrients [116–119]. In this context, T effectors and Treg cells [114,120] are significantly
influenced by metabolism—such an occurrence may explain why caloric excess correlates with
autoimmune diseases [7,57], while hyponutrition increases susceptibility to infections [58–61]. In this
negatively virtuous interplay, the high levels of leptin secreted by the adipose tissue are able to
dysregulate the Treg cells and determine an increased risk of developing autoimmune diseases in
obese patients [121–123].
Reduced Treg cells have been observed in visceral adipose tissue of obese mice and humans.
However, it is unknown whether human obesity affects circulating Treg cells and whether Treg number
is associated with markers of systemic inflammation or glucose intolerance. The effect of human obesity
to reduce Treg levels has been addressed [124,125]. Circulating Treg cells are inversely correlated with
body weight and plasma leptin levels [125].
Reduction of circulating Treg cells in obesity may be caused by their recruitment into an active
inflammation site. In this regard, an upregulated expression of homing receptors—including the
chemokine receptors CXCR3 and CCR7—on the surface of Treg cells and an increased accumulation
of Treg cells in the spleen of obese mice have been reported [126]. Increased serum levels
of adipose tissue-derived cytokines may impair Treg cell maturation and/or survival in obesity.
Interestingly, the receptor of the adipokine leptin is expressed on T lymphocytes [95], including Treg cells,
and leptin neutralization promotes their proliferative capacity [101]. Moreover, hypercholesteraemic
LDL-R mice with defective leptin signalling exhibited improved Treg cell functions [127].
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Adiposity has been associated with increased concentrations of leptin and other proinflammatory
adipokines, cytokines, and acute-phase proteins [128]. The role of adiponectin in dogs still appears
controversial and few data are available in the veterinary literature on the possible impact of obesity
on the immune response. The effects of weight loss on canine adipokines and cytokines have been
reported [2,3,129–131]. Several studies showed that plasma leptin concentrations correlate with body
fat content in experimentally induced obese beagles [132,133]. In this regard, Sagawa et al. highlighted
that the positive relationship between plasma leptin concentration and body fat content in dogs is
similar to correlations reported for humans and rodents [132]. Ishioka et al. [134] showed that plasma
leptin represents an index of adiposity in dogs regardless of their age, gender, and breed variations. It is
well known that plasma leptin concentrations increase with weight gain and decrease with weight loss
in dogs. In this regard, Jeusette et al. [135] described a decrease in ghrelin and an increase in leptin and
insulin concentrations in obese beagle dogs. The same authors [135] suggested that ghrelin and leptin
could play a role in dogs in the adaptation to a positive or negative energy balance, as observed in
humans. Proinflammatory state directly influences glucose metabolism, resulting in decreased insulin
sensitivity [128]. In fact, high-plasma leptin concentrations have been correlated to insulin resistance
in humans [136] and in insulin-resistant dogs [135]. Serum leptin concentrations correlated with
percentage of body fat and decreased with weight loss, whereas the involvement of other inflammatory
markers in canine obesity and weight loss is still less understood. Induction of canine obesity has been
shown to increase concentrations of TNF-α [137] which decreases after a weight loss program in obese
dogs [2]. However, acute phase proteins appeared to be unaltered after the weight loss program [129],
while the production of C-reactive protein decreased in obese dogs [2,129–131,138].
Van de Velde et al. [139] investigated the effect of a short-term increase in body weight on immunological
variables in adult healthy beagle dogs in which weight gain and increased body condition score (BCS)
were accompanied by a significantly higher leptin concentration. Subsequently, the same authors [140]
described that T-cell proliferation is affected after weight gain in Beagle dogs.
Recently, concentrations of IL-6 and monocyte chemoattractant protein 1, but not IL-8, were found
to be increased in overweight dogs [141], whereas other authors described decreasing concentrations of
IL-8 and other interleukins with weight loss in dogs [131]. Piantedosi et al. [142] revealed no significant
differences in serum TNF-α and IL-6 concentrations between obese and normal weight dogs.
Several studies have reported that the systemic circulating leptin deficiency in malnutrition
is also correlated to infectious diseases [61,77,81,143–145] including leishmaniasis [146,147] due to
defective cytokine production [84,148]. Leptin can augment host protective immune response during
experimental visceral leishmaniasis (VL) [146,147]. Indeed, leptin induces the phagocytic activity of
human macrophages against L. donovani infection by enhancing the phagolysosome formation and
oxidative killing of the parasite via intracellular reactive oxygen species (ROS) generation [147].
Palatucci et al. [65] reported that obese Labrador Retrievers are characterized by the inverse
correlation between leptin serum concentration and circulating Treg levels. Moreover, an increased
number of cytotoxic T cell effectors and a higher IFN-γproduction by cytotoxic T lymphocytes have been
observed in obese dogs [65]. However, the relationship between obesity, leptin, and circulating Treg
level, as well as the occurrence of systemic inflammation in dogs and in other domestic mammalians
are still poorly understood.
Increased inflammatory response has been correlated with clinical exacerbation, and the
immunotherapeutic role of Tregs appears to be relevant in leishmaniosis [149].
Tregs function, macrophage activation, and the proinflammatory state appear to be involved in
the pathogenesis of canine leishmaniasis. Naturally L. infantum infected dogs expressed alteration
in leptin gene transcription and low levels of circulating Treg [150]. In the same model, ineffective
immune response to parasites appeared to be associated with high Treg levels [151]. Di Loria et al. [152]
showed an increase in leptin mRNA expression in dogs naturally infected by L. infantum.
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4. Leptin and Associated Diseases in Humans and Dogs
High body mass index represents a risk factor in both human and canine mammary inflammatory
carcinomas [153–156]. How obesity can influence the development and prognosis of human breast cancer
remains unknown, although several factors secreted by adipocytes including aromatase, leptin, adiponectin,
oestrogens, and insulin-like growth factor-1 have been implicated [157]. Leptin may promote carcinogenesis
of the mammary tissue through its interaction with the leptin receptor Ob-R [158–162]. Such a hormone
could affect breast cancer by stimulating growth of normal mammary epithelial cells and tumour cells,
tumour invasion, angiogenesis, and aromatase activity [157,162]. Obesity is considered a pro-inflammatory
state and is associated with increasing circulating levels of TNF-α and IL-6 [163]. Chronic inflammation
promotes tumour development [164], macrophage recruitment in mammary gland in human and murine
obese subjects [165,166] and metastasis of breast tumours [167]. Notably, obesity-related macrophage
infiltration of murine mammary gland reversed with caloric restriction [168].
Obesity affects progression, and metastasis in canine mammary carcinoma (MC) by recruitment
of macrophages [156] (Figure 2). In this regard, macrophage infiltration of tumour areas appears to
be higher in overweight or obese subjects than in lean subjects. In addition, decreased adiponectin
expression and increased macrophage numbers in overweight or obese subjects associate with poor
prognosis, high histological grade, and lymphatic invasion [156]. Leptin and Ob-R expression correlates
with oestrogen receptor status MC [156].
Canine obesity has been associated with cardiac dysfunction [142,169–171]. Leptin has been observed
in canine cardiovascular disease [172,173] (Figure 3). Varied morphologies of human obesity-related
cardiac structural changes have been described and many include symmetric or asymmetric left ventricle
hypertrophy (LVH) with or without left ventricular chamber dilatation [174,175]. In canine model,
Adolphe et al. [170] described alterations in glucose, adipokines (leptin and adiponectin) and heart during
obesity (Figure 3). Weight loss reversed these alterations. Piantedosi et al. [142] suggested the presence of
myocardial concentric hypertrophy in obese dogs.
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Figure 3. Obesity in dogs and diseases associated with hyperleptinemia.
Systolic arterial blood pressure appeared to be higher in obese than in normal weight dogs
(Figure 3). Similar cardi vascular findings and increased systolic blood pressure have been reported
by Mehlman et al. [169]. In contrast, hyperte sion has not been related to canine obesity [176].
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Obese dogs express alterations in cardiac function, insulin resistance, dyslipidaemia,
hypo-adiponectinaemia and increased concentrations of inflammatory markers and leptin [171].
However, only few studies investigated the role of leptin in canine cardiac diseases [169,177,178].
In the heart, cardiomyocytes and endothelial cells produce leptin and express its receptor. In addition
to changes in blood concentrations, functional auto- and paracrine effects may occur [179–182].
Leptin regulates the baseline physiology of the heart including myocyte contractility, hypertrophy,
apoptosis, and metabolism [181,183,184]. Localized depots of epicardial or perivascular fat might
also play physiological or pathological roles [183,185,186]. In cardiac disease (CDi) and in congestive
heart failure (CHF), leptin significantly increased, suggesting that an increased metabolic rate is
associated with high concentrations of catecholamines and proinflammatory cytokines present
in CHF [187,188]. Furthermore, because of elicited central sympathoexcitatory effects, leptin
participates in the neuro-humoral activation in heart failure [189]. Increased leptin has been
associated with increased oxygen consumption and intracellular calcium release and decreased
cardiac efficiency in vivo [179,186,190]. In CDi, leptin is involved in cardiac remodelling, characterized
by cardiomyocyte hypertrophy and disruption of the extracellular matrix resulting in increased collagen
deposition [185,186,191], which might contribute to cardiac dysfunction. Such a hormone protects
cardiomyocytes from apoptosis, which plays an important role in the development of CHF [192].
Leptin might decrease cardiac hypertrophy, apoptosis, and inflammation in deficient leptin receptor
mice [193]. Therefore, leptin can impact cardiovascular function by direct heart effects or by central
nervous system responses and may represent a predictor of cardiovascular morbidity [179,185].
However, the role of leptin in development and progression of canine CDi and CHF is still poorly
understood [172,173].
The role of leptin as a pathophysiological modulator has been described in other canine pathological
conditions [194,195], besides cardiovascular diseases. Adipokines, especially resistin and visfatin, have
been implicated in the development of acute pancreatitis (AP) in humans [196–199] and in experimental
animal models [200–202]. However, little information is available about the circulating adipokine
concentrations during the pathogenesis of AP in dogs. Recently, Paek et al. [203] described that leptin,
resistin, and visfatin were significantly higher in the dogs with AP than in healthy dogs, whereas
adiponectin concentration was significantly lower in AP than in healthy dogs. IL-1b, IL-6, IL-10,
and IL-18 also increased in AP dogs [203]. These results suggest a potential role for adipokines in the
development and modulation of AP in dogs (Figure 3).
In addition, leptin and its receptor play several physiological roles in the canine gallbladder (Figure 3).
Gallbladder is not only a source of leptin, but it is also affected by autocrine/paracrine mechanisms [204].
Lee et al. [205] revealed an increased expression of leptin and leptin receptors in dogs with gallbladder
mucocele (GBM), suggesting that such a hormone plays a role as a causative factor in GBM.
The relationship between serum triglyceride/cholesterol and leptin is still controversial [206,207].
Leptin may correlate with serum lipids in dogs [208,209]. A positive association between human
hyperlipidaemia and gallstones has been described [210,211]. Recently, Lee et al. [212] described an
increase in serum leptin during hyperlipidaemia and cholelithiasis occurrence in dogs.
Finally, leptin is known for its involvement in the regulation of reproductive functions. Such a
hormone is important for uterine receptivity, implantation, placental growth, and maternal energy
homeostasis in several species [213,214]. The uterus and placenta are also sources of leptin and targets
of its actions during gestation in canine species. Leptin and leptin receptors are expressed both in the
foetal and maternal sides of the placenta, thus, a role in placental physiology seems likely. The leptin
signalling system may be one of the pathways involved in the establishment and maintenance of
pregnancy and may also play a regulatory role in parturition in the bitch [215].
5. Conclusions
Leptin constitutes a relevant hormonal “actor” in obesity, immune-system homeostasis and in
several associated metabolic-related as well as immune-mediated diseases [8]. Recent clinical studies
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on autoimmune disease patients demonstrated that high serum leptin levels may play a causal role in
the disease progression and could represent a diagnostic marker for clinical application. It remains
to be established if leptin could be a potential therapeutic target in treating human autoimmune
diseases [30,216].
Circulating leptin correlates with fat mass and is considered a useful marker of adiposity in
veterinary settings. However, no studies are available concerning other clinical applications of such a
hormone, and about the involvement of leptin in canine immune-mediated diseases.
The growing worldwide scientific attention for obesity and leptin—in consideration of the
important implications for quality of life in humans and animals—must motivate further studies,
able to generate information on the molecular mechanism exerted by leptin in the course of the
disease, and to therefore identify possible therapeutic targets for obesity as well as other associated
diseases. Furthermore, the most recent interest in the study of obesity and related diseases in animal
species appears to be intriguingly “translational” to better understand the human etiopathology of the
metabolic syndrome. In fact, domestic animals, particularly the dog, represent the natural biological
indicators of the habits of life in, correlating with human aspects. Therefore, the need for studies to
understand the pro-inflammatory role of leptin and weight gain in canine diseases seems to be of
great importance, not only for veterinary medicine, but also to protect human health and to contain
health-related expenditure generated by many widespread chronic metabolic diseases.
Funding: This research received no external funding.
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